The Amyloid Cardiomyopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Amyloid Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Amyloid Cardiomyopathy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Amyloid Cardiomyopathy and features dormant and discontinued products.
GlobalData tracks 17 drugs in development for Amyloid Cardiomyopathy by 14 companies/universities/institutes. The top development phase for Amyloid Cardiomyopathy is phase iii with six drugs in that stage. The Amyloid Cardiomyopathy pipeline has 16 drugs in development by companies and one by universities/ institutes. Some of the companies in the Amyloid Cardiomyopathy pipeline products market are: Lotus Pharmaceutical, Ionis Pharmaceuticals and Alnylam Pharmaceuticals.
The key targets in the Amyloid Cardiomyopathy pipeline products market include Transthyretin.
The key mechanisms of action in the Amyloid Cardiomyopathy pipeline product include Transthyretin Inhibitor with 12 drugs in Filing rejected/Withdrawn. The Amyloid Cardiomyopathy pipeline products include five routes of administration with the top ROA being Intravenous and five key molecule types in the Amyloid Cardiomyopathy pipeline products market including Small Molecule, and Gene Therapy.
Amyloid Cardiomyopathy overview
Amyloid cardiomyopathy (stiff heart syndrome) is a condition resulting in the death of part of the myocardium (heart muscle). It is associated with the systemic production and release of many amyloidogenic proteins, especially immunoglobulin light chain or transthyretin (TTR).
For a complete picture of Amyloid Cardiomyopathy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
